Wednesday March 14, 6:58 pm Eastern Time
Press Release
SOURCE: Aurora Biosciences Corporation
Aurora Biosciences to Present at ScreenTech 2001
Conference in San Diego
SAN DIEGO, March 14 /PRNewswire/ -- Aurora Biosciences Corporation (Nasdaq:
ABSC - news) today announced that it will make a presentation on Thursday March 15,
2001 at 4:30 PM during the ScreenTech 2001 conference being held at the Sheraton San
Diego Hotel & Marina. The presentation entitled, ``Fluorescence-Based Assay Technologies
for Signal Transduction Targets: Assessment of Performance in HTS and UHTSS®
Formats,'' will be given by Jeffrey Stack, Ph.D., Aurora's group leader, Discovery
Biology-Enzymes.
Dr. Stack's presentation will highlight cell-based and biochemical assay technologies and
discuss results from 10 ultra-high throughput screens run over a six-week period at Aurora.
Approximately 125,000 compounds were tested in each screen.
``These data illustrate the formidable capabilities of our discovery platforms,'' stated Paul
Negulescu, Ph.D., senior vice president, Discovery Biology. ``The one million plus
experiments that we conducted during this campaign put us on track to achieve our
established goals for our Big Biology(TM) initiative, our internal drug discovery program, in
2001.''
Aurora Biosciences® develops and commercializes technologies, products and services to
accelerate the discovery of new medicines. Aurora's core technologies include a broad
portfolio of proprietary fluorescence assay technologies and screening platforms designed to
provide an integrated solution for drug discovery. Our fluorescence assay technologies
include our GeneBLAzer(TM), GenomeScreen(TM), PhosphoryLIGHT(TM) and
Vivid(TM) technologies, as well as a broad collection of fluorescent proteins. Our screening
platforms include our ultra-high throughput screening system, the UHTSS® Platform, our
automated master compound store, the AMCS, and our ion channel technology screening
platform, which includes our proprietary voltage sensor probes and voltage ion probe reader,
the VIPR(TM) subsystem. We also provide assay development and screening services as
part of our drug discovery collaborations. Our Big Biology(TM) Initiative is an internal drug
discovery program focused on the identification of promising preclinical candidates within all major classes of gene targets. Our
technologies and drug discovery capabilities have been commercially validated by over 20 major life sciences companies and
research organizations, including American Home Products, Bristol-Myers Squibb Co., Ceres, Inc., Cystic Fibrosis
Foundation, Eli Lilly & Co., Families of SMA, GlaxoSmithKline, Genentech, Inc., Johnson & Johnson, Merck & Co., Inc.,
NV Organon Laboratories, Pfizer, Inc., Pharmacia and Roche, in the form of commercialization agreements for discovery
collaborations, research services, licenses or systems. For additional information on Aurora's services and products, please
contact Sales and Marketing via email at marcom@aurorabio.com.
Statements in this press release that are not strictly historical are ``forward-looking'' statements which involve a high degree of
technological and competitive risks and uncertainties that exist in Aurora's operations and business environment. Such
statements are only predictions and Aurora's actual events or results may differ materially from those projected in such
forward-looking statements. Factors that could cause or contribute to differences include Aurora's ability to develop and
commercialize new technologies, as well as commercial acceptance of such technologies, Aurora's ability to rapidly identify
promising drug candidates through its Big Biology initiative, Aurora's dependence on patents and proprietary rights, Aurora's
ability to generate additional sales of products and services, Aurora's dependence on pharmaceutical and biotechnology
collaborations and the development or availability of competing technologies, products or services. These factors and others
are more fully described in Aurora's Registration Statement on Form S-4 filed in connection with the merger with PanVera
Corporation, Aurora's Annual Report on Form 10-K/A for the fiscal year ended December 31, 1999, and subsequent filings,
as filed with the Securities and Exchange Commission. For additional corporate information, visit the Aurora website at
aurorabio.com.
Aurora Biosciences®, Big Biology(TM), GeneBLAzer(TM), GenomeScreen(TM), PhosphoryLIGHT(TM), UHTSS®,
VIPR(TM) and Vivid(TM) are trademarks of Aurora Biosciences Corporation.
SOURCE: Aurora Biosciences Corporation |
